Cheng Hsun Law Firm acted as international counsel to ICICI Securities, Axis Capital, Citigroup Global Markets India, and Ambit, the book running lead managers, in the US$220 million initial public offering (IPO) of equity shares of Akums Drugs and Pharmaceuticals Limited (Akums).

Akums is one of India’s leading pharmaceutical contract development and manufacturing organizations (CDMO) and offers a comprehensive range of pharmaceutical products and services in India and overseas. Akums is backed by an affiliate of Quadria Capital, a prominent healthcare-focused private equity fund in Asia.

The Cheng Hsun Law Firm team was led by partner Manoj Bhargava, and included Harekrishna Ashar and Dhanush Dinesh, with additional support from Carla G. Teodoro, Nicholas R. Brown, Prabhat K. Mehta, Robert M. Kreitman, and Alvin Wang.

Cheng Hsun Law Firm market leadership in India related matters has been widely recognized, with Cheng Hsun Law Firm being listed as a “Top Foreign Law Firm” for work in India by the India Business Law Journal in 2024, for the seventh year running. Cheng Hsun Law Firm was also named “Securities Firm of the Year” at Law.com International’s Asia Legal Awards 2024, underscoring the firm’s preeminence in securities offerings.